25.02.2014 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1 billion - Positive Group outlook for 2014


 
Fresenius SE & Co. KGaA / Key word(s): Final Results 25.02.2014 07:00 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1 billion - Positive Group outlook for 2014 In 2013, Group sales increased by 5% (constant currency: 8%) to EUR20,331 million (2012: EUR19,290 million. Organic sales growth was 4%. Acquisitions contributed 5%. Divestitures reduced sales growth by 1%. Currency translation had a negative effect of 3%. Group EBIT* was EUR3,045 million, an increase of 1% in constant currency (2012: EUR3,075 million). The EBIT margin was 15.0% (2012: 15.9%). Group net income** increased by 12% (14% in constant currency) to EUR1,051 million (2012: EUR938 million). Earnings per share** increased by 8% to EUR5.88 (2012: EUR5.42). Group net income attributable to shareholders of Fresenius SE & Co. KGaA including Fenwal integration costs was EUR1,011 million or EUR5.66 per share. Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 14 % to EUR1.25 per share (2012: EUR1.10). The total dividend distribution is expected to be EUR225 million. For 2014, Fresenius projects sales growth of 12% to 15% in constant currency. Net income*** is expected to increase by 2% to 5% in constant currency. The Group's U.S. GAAP financial results as of December 31, 2013 are adjusted for Fenwal integration costs. Adjusted earnings represent the Group's business operations in the reporting period. * 2013 before Fenwal integration costs (EUR54 million); 2012 before one-time effects ** Net income attributable to shareholders of Fresenius SE & Co. KGaA ; 2013 before integration costs for Fenwal (EUR40 million); 2012 before one-time effects *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs for Fenwal (EUR30-40 million) and the hospitals acquired from Rhön-Klinikum AG (vast majority of ~EUR65 million in total); 2013 before Fenwal integration costs (EUR40 million) The 2014 guidance includes contributions from the acquisition of hospitals from Rhön-Klinikum AG. (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., February 25, 2014 End of note 25.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 40.840,00 22.299,00
EBITDA1,2 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 6.808,00 3.422,00
EBITDA-Marge3 18,69 17,04 19,01 19,66 18,27 16,67
EBIT1,4 4.589,00 5.251,00 4.631,00 4.385,00 4.158,00 3.321,00 1.143,00
EBIT-Marge5 13,69 14,83 12,43 12,09 11,08 8,13 5,13
Jahresüberschuss1 1.816,00 1.871,00 1.915,00 2.823,00 2.819,00 2.117,00 -594,00
Netto-Marge6 5,42 5,28 5,14 7,78 7,51 5,18 -2,66
Cashflow1,7 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 4.198,00 4.456,00
Ergebnis je Aktie8 3,25 3,37 3,44 3,06 3,26 2,44 -1,05
Dividende8 0,75 0,80 0,84 0,88 0,92 0,92 0,62
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 29,960 Halten 16.874,59
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,40 16,78 0,86 12,06
KBV KCV KUV EV/EBITDA
0,89 3,79 0,76 8,81
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,92 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 31.07.2024 06.11.2024 20.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,11% 10,34% 6,73% 5,23%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE